

A Phase 2 Study of HB0017 in Psoriasis Patients

NCT06592274

Status	RECRUITING
Phase	Phase 2
Sponsor	Huabo Biopharm Co., Ltd.
Enrollment	200 participants

Key Eligibility Criteria

Inclusion (5)

- Male or female subjects aged 18-75 years (inclusive)
- Chronic plaque psoriasis (PSO) for at least 6 months prior to the randomization.
- Psoriasis Area Severity Index (PASI) ≥ 12 and body surface area (BSA) affected by PSO $\geq 10\%$ and Static Physician Global Assessment (sPGA) score ≥ 3 .
- Subjects who are suitable for systemic treatment or phototherapy for psoriasis as judged by the investigator
- Subjects who are able to use effective contraception from the screening period to 6 months after the last dose

Exclusion (8)

- Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) at screening or baseline Drug-induced psoriasis
- Ongoing use of prohibited treatments
- Any active infection (other than common cold) within 14 days
- Serious infection defined as requiring hospitalization or iv anti-infective(s) within 1 month prior to randomization
- Have previously received any drug that directly targets IL-17 or IL-17 receptor
- ... and 3 more (see full listing online)

Locations (18 total)

The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
Southern Medical University Dermatology Hospital, Guangzhou, Guangdong, China
Xiangya Hospital of Central South University, Changsha, Hunan, China
... and 15 more locations